Bristol Myers Squibb adding 3 medications on TrumpRx

Bristol Myers Squibb will list three drugs on TrumpRx.gov: Sotyktu at $743 (90% off from $7,135.55), Zeposia at an 88–90% discount (relapsing MS), and Orencia SC reduced by 40% (weekly RA injection). The additions follow similar discounts from Amgen (Amjevita $299, ~80% off) and GSK (Incruse $159.20, 55% off), signaling continued White House-driven price concessions. BLS data cited in the article show prescription drug costs up 10.4% from Jan 2021–Jan 2025 and up 0.2% from Jan 2025–Feb 2026.

Analysis

Large-cap, diversified pharma will be the primary absorbers of politically driven price disruptions: scale, therapeutic diversification, and non-U.S. revenue provide immediate mitigation, while mid‑sized specialty franchises and supply partners (CMOs, cold‑chain logistics) face outsized margin pressure if a branded biologic loses pricing leverage. Expect distributors and PBMs to re‑negotiate commercial terms quickly — that will shift economics from list‑price to service and access fees, compressing gross margins but increasing recurring fee income for intermediaries over 6–24 months.

Near‑term catalysts are political headlines and administrative guidance (days–weeks) that create knee‑jerk flow into/away from names; medium‑term risk (3–12 months) is additional program adoption or statutory expansion that can convert isolated discounts into structural net price pressure. Scenario modeling: if 5–10% of specialty revenue faces effective discounts of 40–70%, diversified large caps see low‑single‑digit EPS headwinds, while single‑product or niche biologic owners can see 20%+ earnings volatility.

Second‑order opportunities: acceleration of biosimilar development and faster roll‑outs of manufacturer direct‑to‑patient fulfillment as firms seek to bypass legacy channels; expect increased M&A in contract manufacturing and specialty distribution this year as companies lock supply and control margins. Over a multi‑year horizon, regulatory unpredictability raises value for names with durable, non‑price moats (unique mechanisms, high switching costs) and penalizes those reliant on pricing rather than clinical differentiation.

Key Decisions for Investors

• Overweight AMGN (6–12 month horizon): initiate a core long position (~2–3% NAV) or buy a 9–12 month call spread to capture upside from scale and buyback leverage if policy headlines abate; upside target +15–25% vs downside capped to ~10–12% in an adverse policy scenario — use position sizing to limit drawdown to 2% NAV.
• Pair trade — long AMGN / short GSK (3–9 months): equal notional to express bias toward U.S. commercial robustness and away from names with greater headline sensitivity; target 8–12% relative outperformance, stop-loss if both move >10% in same direction (indicates market‑wide factor move).
• Tail hedge (3–6 months): buy AMGN 3–6 month puts (small allocation, 0.5% NAV) or purchase an index pharma put to protect against rapid expansion of price programs; cost is insurance vs a >15% downside shock if legislation or broader price mandates emerge unexpectedly.